| Literature DB >> 26851378 |
Misol Ahn1, Franck Kalume2, Rose Pitstick2, Abby Oehler2, George Carlson2, Stephen J DeArmond2.
Abstract
Drug discovery for neurodegenerative diseases is particularly challenging because of the discrepancies in drug effects between in vitro and in vivo studies. These discrepancies occur in part because current cell culture systems used for drug screening have many limitations. First, few cell culture systems accurately model human aging or neurodegenerative diseases. Second, drug efficacy may differ between dividing and stationary cells, the latter resembling nondividing neurons in the CNS. Brain aggregates (BrnAggs) derived from embryonic day 15 gestation mouse embryos may represent neuropathogenic processes in prion disease and reflect in vivo drug efficacy. Here, we report a new method for the production of BrnAggs suitable for drug screening and suggest that BrnAggs can model additional neurological diseases such as tauopathies. We also report a functional assay with BrnAggs by measuring electrophysiological activities. Our data suggest that BrnAggs could serve as an effective in vitro cell culture system for drug discovery for neurodegenerative diseases.Entities:
Keywords: Brain aggregates; Dendritic degeneration; Drug screening; Neurodegeneration; Tau.
Mesh:
Substances:
Year: 2016 PMID: 26851378 PMCID: PMC4902861 DOI: 10.1093/jnen/nlv025
Source DB: PubMed Journal: J Neuropathol Exp Neurol ISSN: 0022-3069 Impact factor: 3.685